Late toxicities (LT) in patients affected by locally advanced (LA) oropharyngeal carcinoma (OPC) treated with definitive (chemo)radiotherapy (C)RT: Risk factors and pattern of adverse effects.
Abstract
e18111 Background: Treatment with CRT has a high burden of acute toxicities in OPCs patients, but data regarding LT are scarce. The more favourable prognosis of HPV-positive OPCs increases the importance to evaluate LT. Methods: We conducted a multinational, retrospective analysis of a consecutive series of LA OPCs treated with definitive RT with/without induction and/or concurrent CT, without any relapse or second primary cancer. We analysed the different patterns of LT in terms of type, number and grade (CTCAE v 5.0), as well as the baseline and treatment-related risk factors associated with LT development. We assessed with generalized linear model and binary logistic regression the impact of clinical and treatment related parameters on the number of LT and the development of at least one grade >2 toxicity. Two different models were created, one including the main clinical factors (alcohol consumption, smoking status, body-mass index, weight loss in past 6 months, stage, p16, p16 x smoking status, primary subsite, caregiver presence) and one considering the treatment-related variables (RT fractionation, type of concurrent CT, use of induction CT). Results: We analysed data from 275 patients (81% HPV-positive) treated with C(RT), with a median total dose of 70 Gy, at 14 European centres between 2007 and 2019. With a median follow-up of 6.4 years (range: 0.8–14.9 years), 201 (73%) experienced at least one treatment-related LT (median 2, range 1-5) of any grade. Overall, xerostomia and dysphagia were the most frequent LT, while weight loss and osteoradionecrosis were the most common ≥G3 toxicities. The incidence and severity of each LT are reported in Table 1. The n° of LT was significantly higher in pts who received conventional fractionation vs moderately acceleration or hyperfractionation, and for the primary subsite of soft palate. Conclusions: With the limitation of a retrospective analysis, xerostomia and dysphagia are the most frequent toxicities complained by the patients in the long term follow up of OPC treated with (C)RT. The number of LT is significantly higher in pts who received conventional fractionation, potentially related to the use of less conformal RT techniques, and for primary subsite in soft palate. This pattern of LT represents the benchmark to be compared with what obtained with de-escalation treatments. Pts with LT. Total n° of pts 275 (100%) N (%) N tox G1 N tox G2 N tox G3-4 N° of pts with any-grade of LT (%) 201 (73.1%) 135 (49.1%) 113 (41.1%) 19 (6.9%) Xerostomia 138 (50.1%) 88 (32.0%) 49 (17.8%) 1 (0.3%) Dysphagia 68 (24.7%) 49 (17.8%) 16 (5.8%) 3 (1.1%) Musculoskeletal fibrosis 63 (22.8%) 38 (13.8%) 24 (8.7%) 1 (0.3%) Hypothyroidism 45 (16.4%) 11 (4.0%) 34 (12.4%) 0 Weight loss 37 (13.4 %) 19 (6.9%) 10 (3.6%) 8 (2.9%) Osteoradionecrosis 21 (7.6%) 11 (4.0%) 3 (1.1%) 7 (2.5%) Pain 9 (3.2%) 6 (2.2%) 2 (0.7%) 1 (0.3%)
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (16)
Riccardo Gili
UO Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy
Valentina Mirisola
Polistudium SRL, Milano, Italy
Lisa F. Licitra
Fondazione IRCCS Istituto Nazionale dei Tumori & University of Milan, Milan, Italy
Marta Maddalo
University of Brescia, Brescia, Italy
Jon Cacicedo
Radiation Oncology Department, Hospital Universitario de Cruces/Biobizkaia Health Research Institute, Barakaldo, Spain
Liliana Belgioia
Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Almalina Bacigalupo
Radiation Oncology Policlinico San Martino IRCCS, Genova, Italy
Almudena García Castaño
Hospital Universitario Marqués de Valdecilla, Santander, Spain
Marc Oliva
Institut Català d’Oncologia L’Hospitalet, Institut d’Investigació Biomèdica de Bellvitge, Barcelona
Pierluigi Bonomo
Azienda Ospedaliera Universitaria Careggi, Radiotherapy Unit, Florence, Italy
Giuseppe Sanguineti
Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Roma, Italy
Pierfrancesco Franco
University of Eastern Piedmont - Azienda Ospedaliero Universitaria “Maggiore della Carità”, Novara, Italy
Athanassios Argiris
Thomas Jefferson University, Philadelphia, PA
Amanda Psyrri
Section of Medical Oncology, Department of Internal Medicine, Attikon University Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Ester Orlandi
Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
Paolo Bossi
Department of Biomedical Sciences, Humanitas University, Milan